Cargando…

Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review

BACKGROUND: Preoperative treatment is performed for locally advanced colon cancer with extensive tumor proximity or suspected invasion of skeletal muscles, major organs, and blood vessels. Oxaliplatin-based regimens are often used in preoperative chemotherapy. However, microsatellite instability (MS...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawayama, Hiroshi, Miyamoto, Yuji, Ogawa, Katsuhiro, Ohuchi, Mayuko, Hisano, Yuki, Kato, Moeko, Tubakihara, Hiroki, Yoshida, Naoya, Baba, Hideo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794638/
https://www.ncbi.nlm.nih.gov/pubmed/36574162
http://dx.doi.org/10.1186/s40792-022-01580-w
_version_ 1784860081210261504
author Sawayama, Hiroshi
Miyamoto, Yuji
Ogawa, Katsuhiro
Ohuchi, Mayuko
Hisano, Yuki
Kato, Moeko
Tubakihara, Hiroki
Yoshida, Naoya
Baba, Hideo
author_facet Sawayama, Hiroshi
Miyamoto, Yuji
Ogawa, Katsuhiro
Ohuchi, Mayuko
Hisano, Yuki
Kato, Moeko
Tubakihara, Hiroki
Yoshida, Naoya
Baba, Hideo
author_sort Sawayama, Hiroshi
collection PubMed
description BACKGROUND: Preoperative treatment is performed for locally advanced colon cancer with extensive tumor proximity or suspected invasion of skeletal muscles, major organs, and blood vessels. Oxaliplatin-based regimens are often used in preoperative chemotherapy. However, microsatellite instability (MSI)-high colorectal cancer is often resistant to cytotoxic anticancer agents. Herein, we describe a case of treatment of anticancer drug-resistant MSI-high locally advanced colon cancer and review cases of complete response to immune checkpoint inhibitor therapy for colorectal cancer. CASE PRESENTATION: A 57-year-old woman was referred to our hospital with a large tumor in the descending colon and extensive thoracic and abdominal wall involvement, including the ribs and diaphragm. No distant metastasis was observed. The tumor had perforated the abdominal wall and formed an abscess. Upon visiting our hospital, emergency surgery was performed. An abdominal wall incision was made to drain the abscess and laparoscopic colostomy was performed. Histopathological examination of biopsy specimens revealed an adenocarcinoma with positive immunohistochemical expressions of both CDX2 and CK20. The patient was diagnosed with a descending colon cancer. Genetic examination found MSI-high, Kras mutation (F12G), and wild-type BRAF. After the inflammation improved, chemotherapy with the FOLFIRI regimen was initiated, but the tumor grew rapidly. As a second-line treatment, nivolumab and ipilimumab combination therapy was initiated. After four cycles of these therapies, the patient was administered nivolumab alone for five cycles. Tumor shrinkage was observed and radical surgery was performed. The patient underwent laparoscopic descending colon and partial thoracic and abdominal wall resection. The abdominal wall muscle was dissected from the abdominal cavity, and subcutaneous tissues, diaphragm, ribs were dissected from the body surface. Pathological examination revealed mucus components, fibrous tissues, and no malignant cells, indicating a complete pathological response (pCR). The patient had a good postoperative course and returned to work after being discharged. No recurrence was observed six months postoperatively. CONCLUSIONS: Herein, we report a case of anticancer drug-resistant MSI-high colon cancer that was resected after treatment with immune checkpoint inhibitors, and a pCR was achieved. This new treatment strategy can be used for the treatment of cases that are not responsive to conventional therapies.
format Online
Article
Text
id pubmed-9794638
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-97946382022-12-29 Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review Sawayama, Hiroshi Miyamoto, Yuji Ogawa, Katsuhiro Ohuchi, Mayuko Hisano, Yuki Kato, Moeko Tubakihara, Hiroki Yoshida, Naoya Baba, Hideo Surg Case Rep Case Report BACKGROUND: Preoperative treatment is performed for locally advanced colon cancer with extensive tumor proximity or suspected invasion of skeletal muscles, major organs, and blood vessels. Oxaliplatin-based regimens are often used in preoperative chemotherapy. However, microsatellite instability (MSI)-high colorectal cancer is often resistant to cytotoxic anticancer agents. Herein, we describe a case of treatment of anticancer drug-resistant MSI-high locally advanced colon cancer and review cases of complete response to immune checkpoint inhibitor therapy for colorectal cancer. CASE PRESENTATION: A 57-year-old woman was referred to our hospital with a large tumor in the descending colon and extensive thoracic and abdominal wall involvement, including the ribs and diaphragm. No distant metastasis was observed. The tumor had perforated the abdominal wall and formed an abscess. Upon visiting our hospital, emergency surgery was performed. An abdominal wall incision was made to drain the abscess and laparoscopic colostomy was performed. Histopathological examination of biopsy specimens revealed an adenocarcinoma with positive immunohistochemical expressions of both CDX2 and CK20. The patient was diagnosed with a descending colon cancer. Genetic examination found MSI-high, Kras mutation (F12G), and wild-type BRAF. After the inflammation improved, chemotherapy with the FOLFIRI regimen was initiated, but the tumor grew rapidly. As a second-line treatment, nivolumab and ipilimumab combination therapy was initiated. After four cycles of these therapies, the patient was administered nivolumab alone for five cycles. Tumor shrinkage was observed and radical surgery was performed. The patient underwent laparoscopic descending colon and partial thoracic and abdominal wall resection. The abdominal wall muscle was dissected from the abdominal cavity, and subcutaneous tissues, diaphragm, ribs were dissected from the body surface. Pathological examination revealed mucus components, fibrous tissues, and no malignant cells, indicating a complete pathological response (pCR). The patient had a good postoperative course and returned to work after being discharged. No recurrence was observed six months postoperatively. CONCLUSIONS: Herein, we report a case of anticancer drug-resistant MSI-high colon cancer that was resected after treatment with immune checkpoint inhibitors, and a pCR was achieved. This new treatment strategy can be used for the treatment of cases that are not responsive to conventional therapies. Springer Berlin Heidelberg 2022-12-27 /pmc/articles/PMC9794638/ /pubmed/36574162 http://dx.doi.org/10.1186/s40792-022-01580-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Sawayama, Hiroshi
Miyamoto, Yuji
Ogawa, Katsuhiro
Ohuchi, Mayuko
Hisano, Yuki
Kato, Moeko
Tubakihara, Hiroki
Yoshida, Naoya
Baba, Hideo
Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
title Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
title_full Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
title_fullStr Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
title_full_unstemmed Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
title_short Pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high descending colon cancer: a case report and literature review
title_sort pathologic complete response after laparoscopic surgery following treatment with nivolumab and ipilimumab for anticancer drug-resistant msi-high descending colon cancer: a case report and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794638/
https://www.ncbi.nlm.nih.gov/pubmed/36574162
http://dx.doi.org/10.1186/s40792-022-01580-w
work_keys_str_mv AT sawayamahiroshi pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT miyamotoyuji pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT ogawakatsuhiro pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT ohuchimayuko pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT hisanoyuki pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT katomoeko pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT tubakiharahiroki pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT yoshidanaoya pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview
AT babahideo pathologiccompleteresponseafterlaparoscopicsurgeryfollowingtreatmentwithnivolumabandipilimumabforanticancerdrugresistantmsihighdescendingcoloncanceracasereportandliteraturereview